Pathogenesis of joint damage in rheumatoid arthritis: Evidence of a dominant role for interleukin-1

Bailliere's Best Practice and Research in Clinical Rheumatology

Volumn 13, Issue 4, 1999, Pages 577-597

  Van Den Berg, Wim B ^a   Bresnihan, Barry ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Interleukin 1; Joint damage; Rheumatoid arthritis; Tumour necrosis factor

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

CARTILAGE DEGENERATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EXPERIMENTAL MODEL; HUMAN; JOINT DESTRUCTION; JOINT INJURY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0033391920     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1053/berh.1999.0047     Document Type: Article

References (84)

1. Firestein G S, Zvaifler N J. How important are T cells in chronic rheumatoid synovitis? Arthritis and Rheumatism. 33:1990;768-773.
2. Feldmann M, Brennan F, Maini R N. Role of cytokines in rheumatoid arthritis. Annual Review of Immunology. 14:1996;397-440.
3. Arend W P, Dayer J M. Inhibition of the production and effects of IL-1 and TNFa in RA. Arthritis and Rheumatism. 38:1995;151-160.
4. Saklatvala J. Tumor necrosis factor a stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 322:1986;547-549.
5. Van de Loo A AJ, Van den Berg W B. Effects of murine recombinant IL-1 on synovial joints in mice: Measurement of patellar cartilage metabolism and joint inflammation. Annals of Rheumatic Diseases. 49:1990;238-245.
6. Henderson B, Pettipher E R. Arthritogenic actions of recombinant IL-1 and TNFa in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clinical and Experimental Immunology. 75:1989;306-310.
7. Ghivizzani S C, Kang R, Georgescu H I. Constitutive intra-articular expression of human IL-1β following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis. Journal of Immunology. 159:1997;3604-3612.
8. Yasuo N, Harumoto Y, Toshiyuki K. Membrane associated IL-1 contributes to chronic synovitis in human IL-1a transgenic mice. Arthritis and Rheumatism. 41:1998;S212.
9. Probert L, Plows D, Kontogeorges G, Kollias G. The type I IL-1 receptor acts in series with TNFa to induce arthritis in TNFa transgenic mice. European Journal of Immunology. 25:1995;1794-1797.
10. Van de Loo A AJ, Arntz O J, Otterness I G, van den Berg W B. Protection against cartilage proteoglycan synthesis inhibition by anti-interleukin 1 antibodies in experimental arthritis. Journal of Rheumatology. 19:1992;348-356.
11. Van de Loo A AJ, Joosten L AB, van Lent P LEM. Role of interleukin-1, tumor necrosis factor a and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ cytokine blocking in murine antigen- and zymosan-induced arthritis. Arthritis and Rheumatism. 38:1995;164-172.
12. Otari K, Nita I, Macaulay W. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy. Journal of Immunology. 156:1996;3558-3562.
13. Van Meurs J BJ, van Lent P LEM, Singer I I. IL-1ra prevents expression of the metalloproteinase generated neoepitope VDIPEN in antigen-induced arthritis. Arthritis and Rheumatism. 41:1998;647-656.
14. Van Lent P LEM, van de Loo F AJ, Holthuysen A EM. Major role for IL-1 but not for TNF in early cartilage damage in immune complex arthritis in mice. Journal of Rheumatology. 22:1995;2250-2258.
15. Joosten L AB, Helsen M MA, van den Berg W B. Accelerated onset of collagen-induced arthritis by remote inflammation. Clinical and Experimental Immunology. 97:1994;204-211.
16. Joosten L AB, Lubberts E, Helsen M MA, van den Berg W B. Dual role of IL-12 in early and late stages of murine collagen type II arthritis. Journal of Immunology. 159:1997;4094-4102.
17. Williams R O, Feldmann M, Maini R N. Anti-TNF ameliorates joint disease in murine collagen induced arthritis. Proceedings of the National Academy of Sciences of the USA. 89:1992;9784-9788.
18. Wooley P H, Dutcher J, Widmer M B, Gillis S. Influence of a recombinant human soluble TNF receptor Fc fusion protein on type II collagen induced arthritis in mice. Journal of Rheumatology. 151:1993;6602-6607.
19. Van den Berg W B, Joosten L AB, Helsen M MA, van de Loo A AJ. Amelioration of established murine collagen induced arthritis with anti-IL-1 treatment. Clinical and Experimental Immunology. 95:1994;237-243.
20. Joosten L AB, Helsen M MA, van de Loo F AJ, van den Berg W B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFa, anti-IL-1a/b, and IL-1ra. Arthritis and Rheumatism. 39:1996;797-809.
21. Bakker A C, Joosten L AB, Arntz O J. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human IL-1ra protein in the knee. Arthritis and Rheumatism. 40:1997;893-900.
22. Ku G, Faust T, Lauffer L L. IL-1b converting enzyme inhibition blocks progression of type II collagen induced arthritis in mice. Cytokine. 8:1996;377-386.
23. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory responses in TNFa-deficient mice: A critical requirement for TNFa in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centres, and in the maturation of the humoral immune response. Journal of Experimental Medicine. 184:1996;1397-1411.
24. Mori L, Iselin S, De Libero G, Lesslauer W. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. Journal of Immunology. 157:1996;3178-3182.
25. Lens J W, van den Berg W B, van de Putte L BA, Zwarts W A. Flare-up of antigen induced arthritis in mice after challenge with intravenous antigen: kinetic of antigen in the circulation and localisation of antigen in the arthritic and noninflamed joint. Arthritis and Rheumatism. 29:1986;665-674.
26. Van de Loo A AJ, Arntz O J, Bakker A C. Role of interleukin-1 in antigen-induced exacerbations of murine arthritis. American Journal of Pathology. 146:1995;239-249.
27. Van de Loo A AJ, Arntz O J, van den Berg W B. Flare up of experimental arthritis in mice with murine recombinant IL-1. Clinical and Experimental Immunology. 87:1992;196-202.
28. Van de Loo F AJ, Kuiper S, van Enckevort F HJ. IL-6 ameliorates cartilage destruction during experimental arthritis. A study in IL-6 deficient mice. American Journal of Pathology. 151:1997;177-191.
29. Van de Loo F AJ, Arntz O J, van Enckevort F HJ. Reduced cartilage proteoglycan loss during symosan-induced gonarthritis in NOS2-deficient mice and in anti-IL-1 treated wild type mice, with unabated joint inflammation. Arthritis and Rheumatism. 41:1998;634-646.
30. Brennan F M, Chantry D, Jackson A. Inhibitory effect of TNFa antibodies on synovial cell IL-1 production in rheumatoid arthritis. Lancet. 2:1989;244-247.
31. Deleuran B. Cytokines in RA: localisation in arthritic joint tissue and regulation in vitro. Scandinavian Journal of Rheumatology. 25:1996;1-38.
32. Kuiper S, Joosten L AB, Bendele A M. Different roles of TNFa and IL-1 in murine streptococcal cell wall arthritis. Cytokine. 10:1998;690-702.
33. Makarov S S, Olsen J C, Johston W N. Suppression of experimental arthritis by gene transfer of IL-1ra cDNA. Proceedings of the National Academy of Sciences of the USA. 93:1996;402-406.
34. Georgopoulos S, Plows D, Kollias G. Transmembrane TNF is sufficient to induce localised tissue toxicity and chronic inflammatory arthritis in transgenic mice. Journal of Inflammation. 46:1996;86-97.
35. Van Meurs J BJ, van Lent P LEM, Holthuysen A EM. Kinetics of aggreanse and metalloproteinase induced neoepitopes in various stages of cartilage destruction in murine arthritis. Arthritis and Rheumatism. 42:1999;1128-1139.
36. Van Meurs, J, BJ, van Lent, P, LEM, Holthuysen, A, EM, Expression of MMP induced neoepitope VDIPEN is linked to severe cartilage damage: an essential role of stromelysin in antigen induced arthritis, Arthritis and Rheumatism.
37. Harris E D. Rheumatoid arthritis: pathophysiology and implications for therapy. New England Journal of Medicine. 322:1990;1277-1289.
38. Keyszer G M, Heer A H, Gay S. Cytokines and oncogenes in cellular interactions of rheumatoid arthritis. Stemcells. 12:1994;76-86.
39. Burmester G R, Stuhlmuller B, Keyszer G, Kinne R W. Mononuclear phagocytes and rheumatoid arthritis: mastermind or workhorse in arthritis? Arthritis and Rheumatism. 40:1997;5-18.
40. Youssef, P, Roth, J, Frosch, M, Expression of myeloid-related proteins 8 and 14 and the MRP8/14 heterodimer in rheumatoid arthritis synovial membrane, Journal of Rheumatology.
41. Cunnane G, FitzGerald O, Hummel K M. Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. Rheumatology. 38:1999;34-42.
42. Lacraz S, Isler P, Vey E. Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. Journal of Biological Chemistry. 269:1994;22027-22033.
43. Eastgate J A, Symons J A, Wood N C. Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet. 2:1988;706-709.
44. North J, Situnayake R D, Tikly M. Interleukin-1 beta, hand and foot mineral content and the development of joint erosions in rheumatoid arthritis. Annals of Rheumatic Diseases. 53:1994;543-546.
45. Hopkins S J, Humphreys M, Jayson M IV. Cytokines in synovial fluid 1. The presence of biologically active and immunoreactive IL-1. Clinical and Experimental Immunology. 72:1988;422-427.
46. Fong K Y, Boey M L, Koh W H, Feng P H. Cytokine concentration in the synovial fluid and plasma of rheumatoid arthritis patients: correlation with bony erosions. Clinical and Experimental Rheumatology. 12:1994;55-58.
47. Miyasaka N, Sato K, Goto M. Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients: possible involvement in joint destruction. Arthritis and Rheumatism. 31:1988;480-486.
48. Firestein G S, Alvaro-Garcia J M, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. Journal of Immunology. 144:1990;3347-3352.
49. Wood N C, Dickens E, Symons J A, Duff G W. In situ hybridisation of interleukin-1 in CD14-positive cells in rheumatoid arthritis. Clinical Immunology and Immunopathology. 62:1992;295-300.
50. Chu C Q, Field M, Allard S. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. British Journal of Rheumatology. 31:1992;653-661.
51. Dinarello C A. Biologic basis for interleukin-1 in disease. Blood. 87:1996;2096-2147.
52. Bresnihan B, Cunnane G. Interleukin-1 receptor antagonist. Rheumatic Disease Clinicians of North America. 24:1998;615-628.
53. Arend W P. Interleukin-1 receptor antagonist. Advances in Immunology. 54:1993;167-227.
54. Arend W P, Welgus H G, Thompson R C, Eisenberg S P. Biological properties of recombinant human monocyte-derived interleukin-1 receptor antagonist. Journal of Clinical Investigations. 85:1990;1694-1697.
55. Firestein G S, Boyle D, Yu C. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis and Rheumatism. 37:1994;644-652.
56. Saxne T, Palladino M A, Heinegard D. Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis and Rheumatism. 31:1988;1041-1045.
57. Barrera P, Boerbooms A M, Janssen E M. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis and Rheumatism. 36:1993;1070-1079.
58. di Giovine F S, Nuki G, Duff G W. Tumor necrosis factor in synovial exudates. Annals of Rheumatic Diseases. 47:1988;768-772.
59. Chu C Q, Field M, Feldmann M, Maini R N. Localisation of tumor necrosis factor a in synovial tissues and the cartilage pannus junction in patients with rheumatoid arthritis. Arthritis and Rheumatism. 34:1991;1125-1132.
60. Deleuran B W, Chu C Q, Field M. Localisation of interleukin 1α (IL-1α), type 1 IL-1 receptor and interleukin 1 receptor antagonist protein in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis. British Journal of Rheumatology. 31:1992;601-609.
61. Ogilvie A D, Wood N C, Dickens E. In situ hybridisation. Annals of Rheumatic Diseases. 49:1990;434-439.
62. Husby G, Williams R C Jr. Synovial localisation of tumor necrosis factor in patients with rheumatoid arthritis. Journal of Autoimmunology. 1:1988;363-371.
63. Cope A P, Aderka D, Doherty M. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis and Rheumatism. 34:1992;1160-1169.
64. Roux-Lombard P, Punzi L, Hasler F. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis and Rheumatism. 36:1993;485-489.
65. Deleuran B W, Chu C Q, Field M. Localisation of tumor necrosis factor receptor in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor α Arthritis and Rheumatism. 35:1992;1170-1178.
66. Firestein G S. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors. Arthritis and Rheumatism. 39:1996;1781-1790.
67. Mulherin D, FitzGerald O, Bresnihan B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis and Rheumatism. 39:1996;115-124.
68. Wolfe F, Sharp J T. Radiographic outcome of recent onset rheumatoid arthritis. A 19 year old study of radiographic progression. Arthritis and Rheumatism. 41:1998;1571-1582.
69. Wang A Z, Wang J C, Fisher G W, Diamond H S. Interleukin-1 beta-stimulated invasion of articular cartilage by rheumatoid synovial fibroblasts is inhibited by antibodies to specific integrin receptors and by collagenase inhibitors. Arthritis and Rheumatism. 40:1997;1298-1307.
70. Scott B B, Weisbrot L M, Greewood J D. Rheumatoid arthritis synovial fibroblast and U937 macrophage/monocyte cell line interaction in cartilage degradation. Arthritis and Rheumatism. 40:1997;490-498.
71. Muller-Ladner U, Roberts C R, Franklin B N. Human IL-1Ra gene transfer into human synovial fibroblasts is chondroprotective. Journal of Immunology. 158:1997;3492-3498.
72. Paleolog E M, Young S, Stark A. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis and Rheumatism. 41:1998;1258-1265.
73. Drevlow B E, Lovis R, Haag M A. Recombinant human interleukin-1 receptor type I in the treatment of patient with active rheumatoid arthritis. Arthritis and Rheumatism. 39:1996;257-265.
74. Bresnihan B, Alvaro-Garcia J M, Cobby M. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis and Rheumatism. 41:1998;2196-2204.
75. Jiang, Y, Geuant, H, K, Watt, I, Correlation of Benant and Larsen radiologic scoring methods in a multicenter, double-blind, randomised and placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis.
76. Evans C H, Ghivizzani S C, Kang R. Gene therapy for rheumatic diseases. Arthritis and Rheumatism. 42:1999;1-16.
77. Elliott M J, Maini R N, Feldmann M. Treatment of rheumatoid arthritis with chimerie nomoclonal antibodies to tumor necrosis factor α Arthritis and Rheumatism. 36:1993;1681-1690.
78. Elliott M J, Maini R N, Feldmann M. Randomised double-blind comparison of chimerie monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet. 344:1994;1105-1110.
79. Maini R N, Breedveld F C, Kalden J R. Therapeutic efficacy of multiple intravenous infusion of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis and Rheumatism. 41:1998;1552-1563.
80. Moreland L W, Scott M D, Baumgartner M D. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor(p75)-Fc fusion protein. New England Journal of Medicine. 337:1997;141-147.
81. Mulherin D, FitzGerald O, Bresnihan B. Clinical improvement and radiological deterioration in rheumatoid arthritis: evidence that the pathogenesis of synovial inflammation and articular erosion may differ. British Journal of Rheumatology. 25:1996;1263-1268.
82. Cunnane, G, Madigan, A, Murphy, E, The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis, Journal of Rheumatology.
83. Tak P P, Taylor P C, Breedveld F C. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis and Rheumatism. 39:1996;1077-1081.
84. Brennan F M, Browne K A, Green P A. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatology arthritis patients following anti-tumor necrosis factor-α (cA2) therapy. British Journal of Rheumatology. 36:1997;643-650.